Borgeson Blake 4

What Happened

Blake Borgeson, a director of Recursion Pharmaceuticals (RXRX), sold 220,000 shares on February 3, 2026, at $4.20 per share for proceeds of $924,000. The transaction was a sale (not a purchase) and was reported on a Form 4 filed February 6, 2026.

Key Details

• Transaction date and price: 2026-02-03 at $4.20 per share.
• Shares sold / proceeds: 220,000 shares; total proceeds $924,000.
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Borgeson on August 31, 2025.
• Filing timeliness: Form 4 filed on 2026-02-06 (one business day after the two-business-day filing window), i.e., reported late.

Context

This was an open-market sale executed under a pre-established 10b5-1 plan, which allows insiders to sell according to a predetermined schedule. Sales under 10b5-1 plans are commonly routine and do not by themselves indicate the insider’s current view of the company. Retail investors should note the late filing; while often administrative, late Form 4s reduce the usefulness of insider timing information.